Effect of l-carnitine supplementation on inflammation, blood glucose and lipids in hemodialysis childre

Phase 3

Recruiting

• Conditions: Condition 1: Chronic kidney disease, stage 5. Condition 2: dialysis complications. Condition 3: Dialysis-induced inflammation. Condition 4: Hyperlipidemia. Condition 5: hyperglycemia. Condition 6: carnitine deficiency. Condition 7: Disorder of fatty-acid metabolism.; Chronic kidney disease, stage 5; Kidney dialysis as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure; Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts; Hyperlipidemia, unspecified; Hyperglycemia, unspecified; Other secondary carnitine deficiency; Disorder of fatty-acid metabolism, unspecified; N18.5; Y84.1

• Registration Number: IRCT20170202032367N2
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

at least 2 times a week dialysis
three months pass after dialysis at least
plasma carnitine to carnitine free ratio greater than 0.4 (indicating a lack of carnitine)
desiring to participate in this study

Exclusion Criteria

pregnanacy
use of non-steroidal and steroidal anti-inflammatory, lipid lowering and beta-blocker medications
autoimmune diseases, infectious, inflammatory disease, cardiovascular disease, thyroid disorders, thrombocytopenia
nutritional support (enteral and parenteral nutrition)

Study & Design

• Study Type: interventional
• Study Design: Not specified